Consequences of Direct-to-Consumer Advertising Links to Higher Prices and Less Competition
This articlefocuses on a new study that suggests drug price increases areengineered to cover the costs of Direct-to-Consumer Advertising (DTCA).Drug price trend data from AARP, AHRQ, and prescription drug consumerprice index (CPI) are presented.
Topic headings include:
- AARP Rx Watchdog Report Data
- Flaws in the AARP Report
- Engineered Drug Price Increase
- DTC Ad Spend Chart
- Industry Says No Direct Link to DTC
- Plavix and Medicaid
- Smoking Gun Charts
- Pharmacos Spend More on DTCA When There is No Competition
- Plausible or Dubious?
Read this article now. It’s FREE…
Issue: Vol. 8, No. 10: Nov/Dec 2009
Word Count: 2802